Chronic myelogenous leukemia (also known as chronic myeloid leukemia or CML) is a cancer that affects the bone marrow and blood. It usually develops slowly and often begins without noticeable symptoms. However, if left untreated, it can progress into a more aggressive phase. The good news is that CML is now considered a highly manageable condition, thanks to advances in targeted therapy and long-term care.
The chronic myelogenous leukemia (CML) treatment cost in India ranges from $3,000 to $30,000, depending on the stage of the disease, the specific treatment plan, and the hospital chosen. The cost is significantly lower compared to countries like the United States, where similar treatments may cost over $100,000 per year, or the United Kingdom and Australia, where private leukemia care can also be costly. Due to this significant cost difference, India has become a preferred destination for overseas patients seeking high-quality, yet affordable, treatment for CML.
India is recognized as a leading destination for the treatment of chronic myelogenous leukemia, thanks to its advanced technologies, expert hematologists, and cost-effective care. Today, patients with CML have access to a wide range of treatment techniques that not only control the disease but, in some cases, even offer the potential for long-term remission or cure. The focus is now on personalized, targeted, and minimally invasive therapies, with India offering a full spectrum of international standard options at a fraction of the cost.
The discovery of the Philadelphia chromosome led to a breakthrough in the treatment of CML. Tyrosine Kinase Inhibitors (TKIs) are pills that block the activity of the abnormal BCR-ABL protein. These drugs stop the production of cancerous white blood cells.
These drugs are readily available in India, both as branded medications and high-quality generics, significantly reducing costs. The TKI-based approach is the first choice for nearly all patients and has shown excellent long-term survival rates.
For patients who are resistant to multiple TKIs or have progressed to advanced phases of CML, a stem cell transplant may be recommended. The procedure involves replacing the diseased marrow with healthy donor stem cells.
India offers this at NABH- and JCI-accredited hospitals, with success rates comparable to those in the West. It's typically provided to younger patients or those in a blast crisis who need aggressive care.
One of the most exciting developments in CML treatment is the option to stop TKIs under controlled conditions. If a patient achieves deep molecular remission (characterized by very low BCR-ABL levels) for at least two years, doctors may recommend attempting treatment-free remission.
This strategy reduces long-term costs and improves the patient's quality of life.
In addition to active treatment, supportive therapies are essential to maintain patient well-being:
These services are typically bundled in patient-centric treatment packages, keeping costs transparent and manageable.
Hydroxyurea is an older medication used to lower white blood cell counts rapidly. While it is not a long-term solution or curative, it helps stabilize patients before starting TKI therapy. It's also an option for patients who cannot immediately begin TKIs, such as those who are pregnant.
In the blast crisis phase, when CML behaves like acute leukemia, chemotherapy may be used along with TKIs to control the rapid rise in immature white blood cells. After stabilization, a stem cell transplant is often recommended.
The treatment cost for chronic myelogenous leukemia in India starts at $3,000. While exact costs can vary based on the treatment plan, hospital, and location, India offers some of the most affordable and comprehensive cancer care in the world.
For most patients, the first line of treatment involves targeted therapy with TKIs, such as imatinib, dasatinib, or nilotinib. These oral medications are highly effective, and India offers both branded and generic versions. On average:
Patients who achieve long-term remission with TKIs may need to stay on these medications for many years, although some may qualify for treatment-free remission after 3–5 years of sustained response.
Some patients may need more intensive treatments, especially if the disease progresses or if they are resistant to TKIs. Here's what those options typically cost in India:
Many hospitals in India now offer all-inclusive cancer care packages, especially for international patients. These packages often cover the following:
The starting price for such packages ranges between $3,000 and $10,000, depending on the inclusions.
Long-term monitoring is essential in CML. After the initial treatment is successful, patients are advised to undergo:
These follow-ups typically cost between $100 and $300 per visit, making them very affordable for international patients, even allowing them to fly in annually if needed—or follow up remotely with Indian doctors through teleconsultation.
The cost of treating Chronic Myelogenous Leukemia in India depends on several important factors. Understanding these concepts can help patients and their families plan more effectively, especially those traveling from abroad. Although India is known for offering high-quality and affordable cancer care, the chronic myelogenous leukemia treatment cost in India varies based on your medical condition, treatment approach, and hospital choice.
Patients traveling to India for CML treatment can typically save 60% to 80% compared to treatment costs in countries such as the United States, the United Kingdom, or Australia.
Many international patients often ask, "If the quality of cancer treatment in India is so high, why is it so affordable?" The answer lies in the structure of the Indian healthcare system, the manufacturing process of medicines, and the country's overall cost of living. These factors make the treatment cost for chronic myelogenous leukemia in India not only affordable but also highly competitive on a global scale.
Montash V.., 42, from Kenya
"I was diagnosed with Chronic Myelogenous Leukemia (CML) in Nairobi, but the cost of long-term treatment was overwhelming. After some research, I came across Fortis Hospital in Gurgaon and got in touch with Dr. Rahul Bhargava. From the first consultation, I felt I was in safe hands. The hospital arranged everything for me, from airport pickup to accommodation. The cost of my treatment in India was nearly 70% less than what I would have paid back home. Today, I am on affordable medication, my condition is stable, and I continue follow-ups online with Dr. Bhargava. Choosing India saved my life and my savings."
Fatima A., 35, from UAE
"My brother was diagnosed with CML, and we were anxious about the expensive treatment options available in our country. We discovered affordable treatment options in India and contacted Fortis Memorial Research Institute. The hospital responded quickly and provided us with a complete treatment plan. We met Dr. Rahul Bhargava, whose calm and clear approach gave us confidence. My brother underwent the required tests, started medication, and responded well. Everything—from the tests to medicines—was a fraction of the cost in the UAE. We are extremely thankful for the quality care at such an affordable price."
Samuel D., 55, from Nigeria
"When I heard I had leukemia, I felt hopeless due to the treatment costs in my country. I was referred to Fortis Hospital in India by a former patient. I was amazed at how organized the entire process was. The team guided me throughout the travel, stay, and treatment. I met Dr. Rahul Bhargava, who thoroughly explained the disease and the plan. I began my TKI therapy immediately, and within months, I saw major improvement. The Chronic Myelogenous Leukemia treatment cost in India was not only affordable, but the care was compassionate and top-class."
Elena K., 48, from Ukraine
"Due to the war, my cancer treatment was disrupted. I searched for safe, affordable options and found Fortis in Gurgaon. I contacted their international patient services, and within a week, I had an appointment with Dr. Rahul Bhargava. He recommended a combination of medication and monitoring tests. The staff was kind, the hospital was spotless, and the cost of treatment shocked me—in a good way. It was so much more affordable than in Europe, yet the care felt more personal. I'm now continuing my treatment while staying in Delhi. I recommend India to anyone who's struggling to afford CML treatment."
The average Chronic Myelogenous Leukemia treatment cost in India ranges from $3,000 to $5,500 per year for targeted drug therapy. It includes medications, diagnostic tests, consultations, and follow-up care. If advanced treatments like bone marrow transplants are needed, the total cost may go up to $15,000–$30,000 USD, which is still significantly lower than in Western countries.
Dr. Rahul Bhargava is one of India's most trusted and experienced hematologists. He specializes in blood cancers, such as CML, and is recognized for his compassionate care, accurate diagnosis, and patient-centered treatment plans.
Yes, most of the medications used in CML treatment in India are internationally approved and may be available in your country under different brand names. Your doctor in India can provide you with prescriptions and guidance for continued use at home or help you access the same medicines at Indian prices via medical shipping partners.
Some international insurance companies do offer coverage or reimbursement for treatment abroad, including in India. It's essential to confirm this with your provider in advance. In many cases, the low cost of Chronic Myelogenous Leukemia treatment in India still makes it more affordable than treatment at home with insurance.
Yes, most leading hospitals in India, including Fortis Memorial Research Institute in Gurgaon, have dedicated international patient departments. These teams assist with medical visa invitations, flight planning, and coordination of airport transfers. Patients are often guided step-by-step to ensure a smooth travel and admission process.
You can email your recent blood test reports, biopsy results, and previous treatment records to the hospital's international desk. Most hospitals respond within 24–48 hours with a preliminary treatment plan, estimated duration of stay, and a customized Chronic Myelogenous Leukemia treatment cost in India tailored to your condition.
Yes, hospitals that handle international patients provide interpreters for languages such as Arabic, French, Spanish, Russian, Swahili, and more. It ensures clear communication between the medical team and patients during all stages of CML treatment in India.
Absolutely. International patients are encouraged to bring an attendant with them. Many hospitals offer accommodation assistance for both patients and their families, either within the hospital's guest houses or through partnerships with nearby hotels and apartments.
You can continue your follow-up care virtually. Most hospitals offer online consultations (via Zoom, WhatsApp, or email) with your treating oncologist. They also provide prescriptions and guidance for ongoing medication management, ensuring continuity of care after you return home.
Yes. Reputed hospitals in India maintain strict international infection control standards. Facilities are NABH or JCI accredited, ensuring world-class cleanliness, sterilization, and patient safety protocols. For CML patients, who may have low immunity, these hospitals offer isolation wards and sterile environments as needed.
Most hospitals accept payments through international credit cards, wire transfers, and even payment apps.